SingHealth Investigational Medicine Unit   Report issue

For profit Phase 1 Phase 2 Phase 4
Founded: Singapore Singapore (2000)

Organization Overview

First Clinical Trial
2017
NCT03225456
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

KK Hospital, SingHealth Duke NUS | SingHealth Investigational Medicine Unit | SingHealth Investigational Medicine Unit (IMU) | SingHealth Regional Health System | Translational Immunology Institute

Active Ingredients

Drugs in Phase 4 Trials (5)

acitretin (soriatane) (2 trials)

cyclosporine (sandimmune) (2 trials)

ixekizumab (taltz) (1 trial)

methotrexate (2 trials)

secukinumab (cosentyx) (1 trial)

Drugs in Phase 2 Trials (3)

arct-021 (1 trial)

oxytocin (syntocinon) (1 trial)

sars-cov-2 specific t cells (1 trial)

Drugs in Phase 1 Trials (2)

ty027 (1 trial)

tyzivumab (1 trial)

Drugs in Other Trials (1)

glycerin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronavirus Infections (Phase 1)

Psoriasis (Phase 4)

Virus Diseases (Phase 1)

Weight Gain (Phase 2)

Zika Virus Infection (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 8
  • # of Trial APIs: 11